<DOC>
	<DOC>NCT00485875</DOC>
	<brief_summary>The purpose of this study is to assess changes in ADHD symptoms and tolerability of medication in children and adolescents switching from a stimulant to atomoxetine.</brief_summary>
	<brief_title>Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Patients must be at least 6 years of age and not yet be 18 years of age at the completion of visit 6 Patients must meet DSMIV diagnostic criteria for ADHD (any subtype) Patients must have laboratory results showing no significant abnormalities (significant would include laboratory deviations requiring acute medical intervention or further medical evaluation) Patients must be of normal intelligence as assessed by the investigator (that is, without a general impairment of intelligence and likely, in the investigator's judgment, to achieve a score of greater than or equal to 70 on a IQ test) Patients must be able to swallow capsules Patients who weigh less than 22 kg or more than 70 kg at study entry Patients who have a history of Bipolar I or Bipolar II Disorder, psychosis, or a pervasive developmental disorder Patients with a history of any seizure disorder (other than febrile seizures) or prior EEG abnormalities related to epilepsy, or patients who have taken (or are currently taking) anticonvulsants for seizure control Patients with a history of severe allergies to more than one class of medication, or multiple adverse drug reactions Patients who have glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>